Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Cash & Equivalents: 2009-2025

Historic Cash & Equivalents for Myriad Genetics (MYGN) over the last 16 years, with Sep 2025 value amounting to $145.4 million.

  • Myriad Genetics' Cash & Equivalents rose 45.55% to $145.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $145.4 million, marking a year-over-year increase of 45.55%. This contributed to the annual value of $102.4 million for FY2024, which is 22.48% down from last year.
  • Per Myriad Genetics' latest filing, its Cash & Equivalents stood at $145.4 million for Q3 2025, which was up 95.43% from $74.4 million recorded in Q2 2025.
  • Over the past 5 years, Myriad Genetics' Cash & Equivalents peaked at $295.2 million during Q3 2021, and registered a low of $53.6 million during Q1 2023.
  • For the 3-year period, Myriad Genetics' Cash & Equivalents averaged around $97.1 million, with its median value being $96.9 million (2024).
  • Per our database at Business Quant, Myriad Genetics' Cash & Equivalents spiked by 149.54% in 2021 and then plummeted by 77.89% in 2022.
  • Quarterly analysis of 5 years shows Myriad Genetics' Cash & Equivalents stood at $257.4 million in 2021, then crashed by 77.89% to $56.9 million in 2022, then spiked by 132.16% to $132.1 million in 2023, then fell by 22.48% to $102.4 million in 2024, then skyrocketed by 45.55% to $145.4 million in 2025.
  • Its Cash & Equivalents stands at $145.4 million for Q3 2025, versus $74.4 million for Q2 2025 and $91.8 million for Q1 2025.